Literature DB >> 7489981

Evidence for the presence of an inactive precursor of human hepatocyte growth factor in plasma and sera of patients with liver diseases.

N Arakaki1, S Kawakami, O Nakamura, T Ohnishi, H Miyazaki, T Ishii, H Tsubouchi, Y Daikuhara.   

Abstract

Human hepatocyte growth factor (hHGF), which is now known to be the same protein as the scatter factor and the tumor cytotoxic factor, is a heterodimeric protein with one heavy chain and one light chain linked together by a disulfide bond, and is thought to be involved in liver regeneration. Using an enzyme-linked immunosorbent assay (ELISA) and Western blot analysis, we found that a significant amount of single chain precursor of hHGF (pro-hHGF) was present in plasma of patients with fulminant hepatic failure (FHF) and that normal human serum contained a protease or proteases that convert pro-HGF to a heterodimeric (mature) form of hHGF. We also showed that the processing protease activity for hHGF was suppressed by such serine protease inhibitors as leupeptin, antipain, and aprotinin, and that sera of patients with liver diseases such as fulminant hepatic failure, acute hepatitis, chronic hepatitis, and cirrhosis contained not only pro-hHGF but also the protease. This is the first report showing the presence of pro-hHGF in human blood, and our observations suggest that hHGF is synthesized and secreted from the hHGF-producing cells as an inactive pro-hHGF after hepatic injuries, and the pro-hHGF is then converted to an active heterodimeric form of hHGF in the blood. It is also suggested that plasma of patients with liver diseases contains an active protease or proteases that convert pro-hHGF to a mature form of hHGF.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489981

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

1.  Invasiveness of hepatocellular carcinoma cell lines: contribution of membrane-type 1 matrix metalloproteinase.

Authors:  K Murakami; R Sakukawa; T Ikeda; T Matsuura; S Hasumura; S Nagamori; Y Yamada; I Saiki
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

2.  Combined systemic elimination of MET and epidermal growth factor receptor signaling completely abolishes liver regeneration and leads to liver decompensation.

Authors:  Shirish Paranjpe; William C Bowen; Wendy M Mars; Anne Orr; Meagan M Haynes; Marie C DeFrances; Silvia Liu; George C Tseng; Anastasia Tsagianni; George K Michalopoulos
Journal:  Hepatology       Date:  2016-10-01       Impact factor: 17.425

3.  Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology.

Authors:  P Harvey; A Warn; S Dobbin; N Arakaki; Y Daikuhara; M C Jaurand; R M Warn
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

4.  Prognostic impact of surgical complications and preoperative serum hepatocyte growth factor in hepatocellular carcinoma patients after initial hepatectomy.

Authors:  Toru Mizuguchi; Minoru Nagayama; Makoto Meguro; Toshihito Shibata; Shinsuke Kaji; Takayuki Nobuoka; Yasutoshi Kimura; Tomohisa Furuhata; Koichi Hirata
Journal:  J Gastrointest Surg       Date:  2008-10-10       Impact factor: 3.452

5.  Improvement of sepsis by hepatocyte growth factor, an anti-inflammatory regulator: emerging insights and therapeutic potential.

Authors:  Shinya Mizuno; Toshikazu Nakamura
Journal:  Gastroenterol Res Pract       Date:  2012-02-28       Impact factor: 2.260

6.  Liver Failure Impairs the Intrahepatic Elimination of Interleukin-6, Tumor Necrosis Factor-Alpha, Hepatocyte Growth Factor, and Transforming Growth Factor-Beta.

Authors:  Dawid Porowski; Agnieszka Wirkowska; Ewa Hryniewiecka; Janusz Wyzgał; Marek Pacholczyk; Leszek Pączek
Journal:  Biomed Res Int       Date:  2015-05-21       Impact factor: 3.411

7.  Clinical impact of real-time evaluation of the biological activity and degradation of hepatocyte growth factor.

Authors:  Fariba Nayeri; Tayeb Nayeri; Daniel Aili; Lars Brudin; Bo Liedberg
Journal:  Growth Factors       Date:  2008-06       Impact factor: 2.511

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.